FMP
Savara Inc.
SVRA
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
3.28 USD
0.08 (2.44%)
Valuation Date:
Dec 26, 2024 4:00 PM
Share Price on Valuation Date
$3.28
Stock Beta
1.017
Shares Outstanding
171619000